Welcome to our dedicated page for Rxsight SEC filings (Ticker: RXST), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Reading RxSight’s SEC filings can feel like navigating both Wall Street ledgers and FDA rule books at once. Financial metrics sit beside ophthalmic device trial data, and key details about Light Adjustable Lens adoption hide deep within risk sections. Stock Titan’s AI turns that complexity into clarity in real time.
Rather than combing through a 300-page annual report, open our dashboard and see the exact pages where management discusses surgeon utilization or reimbursement trends. Our tool automatically surfaces:
- Highlights from every RxSight annual report 10-K simplified for revenue sources and regulatory milestones
- Segment trends inside each RxSight quarterly earnings report 10-Q filing with side-by-side comps
- RxSight 8-K material events explained minutes after they hit EDGAR
- RxSight insider trading Form 4 transactions and director purchases, plus Form 4 insider transactions real-time alerts
- Key vote items from the latest proxy statement executive compensation disclosures
Have a plain-language question like “How much did RxSight’s executives earn last year?” or “What changed in LAL gross margins?” Simply type it in—our engine is tuned for understanding RxSight SEC documents with AI. You’ll get an answer, the source paragraph, and a link straight to the filing.
Whether you’re tracking RxSight earnings report filing analysis before an investor call or monitoring executive stock transactions Form 4 for sentiment shifts, Stock Titan delivers the full filing set, continuously updated, without the technical jargon. Complex medical-device disclosures, explained simply.
Divisadero Street Capital and affiliated entities, together with William Zolezzi, report beneficial ownership of 218,918 shares of RxSight common stock, representing approximately 0.5% of the class. The filing shows no sole voting or dispositive power and reports shared voting and dispositive power over 218,918 shares, indicating coordinated control among the reporting persons rather than individual sole authority. The report states these securities are directly owned by advisory clients of Divisadero Street Capital Management and that no advisory client holds more than 5% of the class.
The filing is submitted as a Schedule 13G/A by the investment-adviser and affiliated entities and includes a joint filing agreement and an exhibit identifying the control person.
Bank of America Corporation reports beneficial ownership of 172,091 shares of RxSight, Inc. common stock, representing 0.4% of the class. The filing shows 0 shares with sole voting or dispositive power, 151,216 shares with shared voting power and 172,091 with shared dispositive power, reflecting holdings across Bank of America and several wholly owned subsidiaries. The statement affirms the shares are held in the ordinary course of business and were not acquired to change or influence control of the issuer. Ownership is below the 5% threshold that typically signals a controlling stake.
Artisan Partners reports beneficial ownership of 2,252,544 shares of RxSight common stock, representing 5.5% of the class based on 40,636,981 shares outstanding as stated in the filing. The reporting group discloses no sole voting or dispositive power and instead reports 2,041,668 shares with shared voting power and 2,252,544 shares with shared dispositive power.
The shares were acquired on behalf of discretionary clients of Artisan Partners Limited Partnership and the filers certify the holdings are in the ordinary course of business and not held to influence control. A Joint Filing Agreement among the reporting persons is included as an exhibit.
FAQ
What is the current stock price of Rxsight (RXST)?
What is the market cap of Rxsight (RXST)?
